News
-
-
PRESS RELEASE
Medios expects further growth in revenue and earnings after record year 2024
Medios expects further growth in revenue and earnings after a record year in 2024. Consolidated revenue up 5.5% to €1.9 billion. EBITDA pre1 margin reaches 4.2%. Positive outlook for 2025 with revenue expected to reach €2.0 billion -
-
-
PRESS RELEASE
Résultats 2024 : amélioration de la profitabilité et forte génération de trésorerie au 2ème semestre
Exail Technologies affiche des performances record en 2024 avec une forte croissance des indicateurs financiers tels que les prises de commandes, les revenus et l'EBITDA. Perspectives prometteuses dans le secteur de la défense -
PRESS RELEASE
Full-year 2024 results: improved profitability and strong cash generation in the second half
Exail Technologies excels in 2024 with strong financial performance, record order intake, revenue growth, EBITDA improvement, and debt reduction. Strategic success in defense sector. Perspectives focus on drone systems and defense markets -
-
PRESS RELEASE
Steyr Motors AG is considering initial acquisitions to further develop its expansion and profitability alongside strong global organic growth
Steyr Motors AG plans initial acquisitions to boost expansion and profitability amid strong organic growth. The Austrian company targets European and Asian markets for new acquisitions -
PRESS RELEASE
CROSSJECT fait le point sur sa collaboration avec ETON PHARMACEUTICALS, Inc. et sur le programme ZENEO® Hydrocortisone dans le domaine de l'insuffisance surrénale
CROSSJECT renforce sa collaboration avec ETON PHARMACEUTICALS pour le programme ZENEO® Hydrocortisone dans l'insuffisance surrénale, avec des depôts de dossiers prévus à partir de S2 2026 -
PRESS RELEASE
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program
CROSSJECT enhances collaboration with ETON PHARMACEUTICALS Inc. on ZENEO adrenal insufficiency program, introducing new hydrocortisone formulation for the hospital market
